Safety of regadenoson, an adenosine A2A receptor agonist for myocardial perfusion imaging, in mild asthma and moderate asthma patients: A ... View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2008-05

AUTHORS

Brian R. Leaker, B. O’Connor, Trevor T. Hansel, Peter J. Barnes, Lixen Meng, Vandana S. Mathur, Hsiao D. Lieu

ABSTRACT

BACKGROUND: Patients with reactive airways are at risk for adenosine-induced bronchoconstriction, mediated via A(2B) and/or A(3) adenosine receptors. METHODS AND RESULTS: To examine the effects of regadenoson, a selective adenosine A(2A) receptor agonist, on airway resistance, we conducted a randomized, double-blind, placebo-controlled crossover trial in asthmatic patients with a positive adenosine monophosphate challenge test. The mean ratio of the forced expiratory volume in 1 second (FEV(1)) at each tested time point relative to the baseline FEV(1) was significantly higher after treatment with regadenoson compared with placebo from 10 to 60 minutes after treatment. One patient had a substantial but asymptomatic FEV(1) reduction (-36.2%) after regadenoson that reversed spontaneously. The most common adverse events with regadenoson were tachycardia (66%), dizziness (53%), headache (45%), and dyspnea (34%). The mean heart rate significantly increased with regadenoson (maximum of +10.4 beats/min) versus placebo. CONCLUSIONS: In this pilot safety study of 48 patients with mild or moderate asthma who had bronchial reactivity to adenosine monophosphate, regadenoson was safe and well tolerated. More... »

PAGES

329-336

Identifiers

URI

http://scigraph.springernature.com/pub.10.1016/j.nuclcard.2008.02.009

DOI

http://dx.doi.org/10.1016/j.nuclcard.2008.02.009

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1037812905

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/18513639


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Cardiorespiratory Medicine and Haematology", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adenosine A2 Receptor Antagonists", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Asthma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Coronary Artery Disease", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Double-Blind Method", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Exercise Test", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pilot Projects", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Placebo Effect", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Purines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pyrazoles", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Respiration Disorders", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Risk Assessment", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Risk Factors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "name": [
            "From the Pulmonology, Heart and Lung Centre, London, England"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Leaker", 
        "givenName": "Brian R.", 
        "id": "sg:person.01327066420.63", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01327066420.63"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "From the Pulmonology, Heart and Lung Centre, London, England"
          ], 
          "type": "Organization"
        }, 
        "familyName": "O\u2019Connor", 
        "givenName": "B.", 
        "id": "sg:person.01012400567.25", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01012400567.25"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "From the Pulmonology, Heart and Lung Centre, London, England"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hansel", 
        "givenName": "Trevor T.", 
        "id": "sg:person.01311065707.38", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01311065707.38"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "From the Pulmonology, Heart and Lung Centre, London, England"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Barnes", 
        "givenName": "Peter J.", 
        "id": "sg:person.01045564377.55", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01045564377.55"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Gilead Sciences (United States)", 
          "id": "https://www.grid.ac/institutes/grid.418227.a", 
          "name": [
            "Biostatistics, CV Therapeutics, Palo Alto, Calif."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Meng", 
        "givenName": "Lixen", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Gilead Sciences (United States)", 
          "id": "https://www.grid.ac/institutes/grid.418227.a", 
          "name": [
            "Clinical Research, CV Therapeutics, Palo Alto, Calif."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mathur", 
        "givenName": "Vandana S.", 
        "id": "sg:person.01077014765.45", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01077014765.45"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Gilead Sciences (United States)", 
          "id": "https://www.grid.ac/institutes/grid.418227.a", 
          "name": [
            "Clinical Research, CV Therapeutics, Palo Alto, Calif."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lieu", 
        "givenName": "Hsiao D.", 
        "id": "sg:person.0654506263.79", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0654506263.79"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1016/s0140-6736(98)10019-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009352689"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1067/mhj.2001.116070", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012604102"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0735-6757(93)90138-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016818117"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0165-6147(98)01179-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017804473"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.jcmg.2008.02.003", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021315962"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1378/chest.127.6.2222", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024504709"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0735-1097(94)90424-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025970600"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00003088-200645120-00005", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027091187", 
          "https://doi.org/10.2165/00003088-200645120-00005"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00003088-200645120-00005", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027091187", 
          "https://doi.org/10.2165/00003088-200645120-00005"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1378/chest.89.3.335", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040848762"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/(sici)1098-2299(199611/12)39:3/4<333::aid-ddr14>3.0.co;2-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042024088"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1152/ajplung.00353.2002", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1063195609"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1177/096032719401300407", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1063901801"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1177/096032719401300407", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1063901801"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1378/chest.106.4.1083", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1067171984"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.4049/jimmunol.172.12.7726", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1076850170"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2008-05", 
    "datePublishedReg": "2008-05-01", 
    "description": "BACKGROUND: Patients with reactive airways are at risk for adenosine-induced bronchoconstriction, mediated via A(2B) and/or A(3) adenosine receptors.\nMETHODS AND RESULTS: To examine the effects of regadenoson, a selective adenosine A(2A) receptor agonist, on airway resistance, we conducted a randomized, double-blind, placebo-controlled crossover trial in asthmatic patients with a positive adenosine monophosphate challenge test. The mean ratio of the forced expiratory volume in 1 second (FEV(1)) at each tested time point relative to the baseline FEV(1) was significantly higher after treatment with regadenoson compared with placebo from 10 to 60 minutes after treatment. One patient had a substantial but asymptomatic FEV(1) reduction (-36.2%) after regadenoson that reversed spontaneously. The most common adverse events with regadenoson were tachycardia (66%), dizziness (53%), headache (45%), and dyspnea (34%). The mean heart rate significantly increased with regadenoson (maximum of +10.4 beats/min) versus placebo.\nCONCLUSIONS: In this pilot safety study of 48 patients with mild or moderate asthma who had bronchial reactivity to adenosine monophosphate, regadenoson was safe and well tolerated.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1016/j.nuclcard.2008.02.009", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1106202", 
        "issn": [
          "1071-3581", 
          "1532-6551"
        ], 
        "name": "Journal of Nuclear Cardiology", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "3", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "15"
      }
    ], 
    "name": "Safety of regadenoson, an adenosine A2A receptor agonist for myocardial perfusion imaging, in mild asthma and moderate asthma patients: A randomized, double-blind, placebo-controlled trial", 
    "pagination": "329-336", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "b4216bd02a858e25d9ea2a18794758823d7b942ca396ec5135546fe4b82a0777"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "18513639"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "9423534"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1016/j.nuclcard.2008.02.009"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1037812905"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1016/j.nuclcard.2008.02.009", 
      "https://app.dimensions.ai/details/publication/pub.1037812905"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T23:30", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8693_00000537.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1016%2Fj.nuclcard.2008.02.009"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1016/j.nuclcard.2008.02.009'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1016/j.nuclcard.2008.02.009'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1016/j.nuclcard.2008.02.009'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1016/j.nuclcard.2008.02.009'


 

This table displays all metadata directly associated to this object as RDF triples.

234 TRIPLES      21 PREDICATES      61 URIs      39 LITERALS      27 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1016/j.nuclcard.2008.02.009 schema:about N06f799c9fdc94566b33eba95c441d24d
2 N2a57d526eb674c6088fb6dcebe07f799
3 N463e9399ab7440a3bd2019e64830b59c
4 N47b58c60abac497482860aa0b92b7a57
5 N557b98711651439e9fcb2ac615611579
6 N70c0356756ae48559906b5bef89e475b
7 N892c8ad6c60847d7976d63ba822cfa92
8 N9ed888e73af840b995fba1bafc4ded64
9 Nabb92aa066664b848c1bf88cf1f34a17
10 Nabca68a03ca84614a6388eb2bb350335
11 Nade1aa01a12045d2acb5453ad3491908
12 Nb2a9359408d74172807dfdca4ffe05e1
13 Nc5056153531c4a758a46e4d71a9a6deb
14 Nc571770c4f7a486fb242eaab69d70b72
15 Nce819a7a369f4040819f1587b5941c24
16 Nda5c8149edcf4376be4a4b1907d83a1b
17 Nf071ad1235054a0ba0dca6a88bea24bf
18 Nf8495db2ce9240eb943ceebc272e1956
19 anzsrc-for:11
20 anzsrc-for:1102
21 schema:author Ne37a865f5247490a9d244152c074c3ed
22 schema:citation sg:pub.10.2165/00003088-200645120-00005
23 https://doi.org/10.1002/(sici)1098-2299(199611/12)39:3/4<333::aid-ddr14>3.0.co;2-2
24 https://doi.org/10.1016/0735-1097(94)90424-3
25 https://doi.org/10.1016/0735-6757(93)90138-2
26 https://doi.org/10.1016/j.jcmg.2008.02.003
27 https://doi.org/10.1016/s0140-6736(98)10019-3
28 https://doi.org/10.1016/s0165-6147(98)01179-1
29 https://doi.org/10.1067/mhj.2001.116070
30 https://doi.org/10.1152/ajplung.00353.2002
31 https://doi.org/10.1177/096032719401300407
32 https://doi.org/10.1378/chest.106.4.1083
33 https://doi.org/10.1378/chest.127.6.2222
34 https://doi.org/10.1378/chest.89.3.335
35 https://doi.org/10.4049/jimmunol.172.12.7726
36 schema:datePublished 2008-05
37 schema:datePublishedReg 2008-05-01
38 schema:description BACKGROUND: Patients with reactive airways are at risk for adenosine-induced bronchoconstriction, mediated via A(2B) and/or A(3) adenosine receptors. METHODS AND RESULTS: To examine the effects of regadenoson, a selective adenosine A(2A) receptor agonist, on airway resistance, we conducted a randomized, double-blind, placebo-controlled crossover trial in asthmatic patients with a positive adenosine monophosphate challenge test. The mean ratio of the forced expiratory volume in 1 second (FEV(1)) at each tested time point relative to the baseline FEV(1) was significantly higher after treatment with regadenoson compared with placebo from 10 to 60 minutes after treatment. One patient had a substantial but asymptomatic FEV(1) reduction (-36.2%) after regadenoson that reversed spontaneously. The most common adverse events with regadenoson were tachycardia (66%), dizziness (53%), headache (45%), and dyspnea (34%). The mean heart rate significantly increased with regadenoson (maximum of +10.4 beats/min) versus placebo. CONCLUSIONS: In this pilot safety study of 48 patients with mild or moderate asthma who had bronchial reactivity to adenosine monophosphate, regadenoson was safe and well tolerated.
39 schema:genre research_article
40 schema:inLanguage en
41 schema:isAccessibleForFree false
42 schema:isPartOf N8f804355aa054d758207b3c6c6245eee
43 Nf8834bd8893d4a81a81ca8c581183480
44 sg:journal.1106202
45 schema:name Safety of regadenoson, an adenosine A2A receptor agonist for myocardial perfusion imaging, in mild asthma and moderate asthma patients: A randomized, double-blind, placebo-controlled trial
46 schema:pagination 329-336
47 schema:productId N14d0f08c42fb4a66b7757176030a38f4
48 N397586a639bb40a4b3a5d80f5ba3b2c0
49 N56e35b2924f440579c3482fa10ad1825
50 N762681f49df842ab8fc20deefc4011a2
51 Nde34a502890b44e6b0efc35c7c341d4d
52 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037812905
53 https://doi.org/10.1016/j.nuclcard.2008.02.009
54 schema:sdDatePublished 2019-04-10T23:30
55 schema:sdLicense https://scigraph.springernature.com/explorer/license/
56 schema:sdPublisher Nb2d183fb918d4e9c82ca4190d7ce148d
57 schema:url http://link.springer.com/10.1016%2Fj.nuclcard.2008.02.009
58 sgo:license sg:explorer/license/
59 sgo:sdDataset articles
60 rdf:type schema:ScholarlyArticle
61 N04c4be005e9c4ac3b02a8fc96dd70922 rdf:first sg:person.01045564377.55
62 rdf:rest N45210564a1664b12af3bcb924f06b60b
63 N06f799c9fdc94566b33eba95c441d24d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
64 schema:name Pilot Projects
65 rdf:type schema:DefinedTerm
66 N14d0f08c42fb4a66b7757176030a38f4 schema:name pubmed_id
67 schema:value 18513639
68 rdf:type schema:PropertyValue
69 N2a57d526eb674c6088fb6dcebe07f799 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
70 schema:name Risk Factors
71 rdf:type schema:DefinedTerm
72 N397586a639bb40a4b3a5d80f5ba3b2c0 schema:name readcube_id
73 schema:value b4216bd02a858e25d9ea2a18794758823d7b942ca396ec5135546fe4b82a0777
74 rdf:type schema:PropertyValue
75 N45210564a1664b12af3bcb924f06b60b rdf:first N93b28cebfda6400abac08e850b9757a7
76 rdf:rest Na0adbf0d48d94069a02f12abc0dcf616
77 N463e9399ab7440a3bd2019e64830b59c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
78 schema:name Exercise Test
79 rdf:type schema:DefinedTerm
80 N46e513a946654bd7ab5a511c6cfade05 rdf:first sg:person.01311065707.38
81 rdf:rest N04c4be005e9c4ac3b02a8fc96dd70922
82 N47b58c60abac497482860aa0b92b7a57 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
83 schema:name Placebo Effect
84 rdf:type schema:DefinedTerm
85 N557b98711651439e9fcb2ac615611579 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
86 schema:name Treatment Outcome
87 rdf:type schema:DefinedTerm
88 N56e35b2924f440579c3482fa10ad1825 schema:name dimensions_id
89 schema:value pub.1037812905
90 rdf:type schema:PropertyValue
91 N70c0356756ae48559906b5bef89e475b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
92 schema:name Pyrazoles
93 rdf:type schema:DefinedTerm
94 N762681f49df842ab8fc20deefc4011a2 schema:name nlm_unique_id
95 schema:value 9423534
96 rdf:type schema:PropertyValue
97 N82566c25ea484e2a9fe3d4c0a380cc78 schema:name From the Pulmonology, Heart and Lung Centre, London, England
98 rdf:type schema:Organization
99 N892c8ad6c60847d7976d63ba822cfa92 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
100 schema:name Adenosine A2 Receptor Antagonists
101 rdf:type schema:DefinedTerm
102 N8f804355aa054d758207b3c6c6245eee schema:volumeNumber 15
103 rdf:type schema:PublicationVolume
104 N93b28cebfda6400abac08e850b9757a7 schema:affiliation https://www.grid.ac/institutes/grid.418227.a
105 schema:familyName Meng
106 schema:givenName Lixen
107 rdf:type schema:Person
108 N9ed888e73af840b995fba1bafc4ded64 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
109 schema:name Middle Aged
110 rdf:type schema:DefinedTerm
111 Na0adbf0d48d94069a02f12abc0dcf616 rdf:first sg:person.01077014765.45
112 rdf:rest Nb8b094d046424f4a827675edd87e832a
113 Nabb92aa066664b848c1bf88cf1f34a17 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
114 schema:name Humans
115 rdf:type schema:DefinedTerm
116 Nabca68a03ca84614a6388eb2bb350335 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
117 schema:name Asthma
118 rdf:type schema:DefinedTerm
119 Nade1aa01a12045d2acb5453ad3491908 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
120 schema:name Double-Blind Method
121 rdf:type schema:DefinedTerm
122 Nb2a9359408d74172807dfdca4ffe05e1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
123 schema:name Risk Assessment
124 rdf:type schema:DefinedTerm
125 Nb2d183fb918d4e9c82ca4190d7ce148d schema:name Springer Nature - SN SciGraph project
126 rdf:type schema:Organization
127 Nb573293c1fb94d84903c3d48943a44e4 rdf:first sg:person.01012400567.25
128 rdf:rest N46e513a946654bd7ab5a511c6cfade05
129 Nb8b094d046424f4a827675edd87e832a rdf:first sg:person.0654506263.79
130 rdf:rest rdf:nil
131 Nba6d931d3bd9491389cff46c4c4989f4 schema:name From the Pulmonology, Heart and Lung Centre, London, England
132 rdf:type schema:Organization
133 Nc5056153531c4a758a46e4d71a9a6deb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
134 schema:name Adult
135 rdf:type schema:DefinedTerm
136 Nc571770c4f7a486fb242eaab69d70b72 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
137 schema:name Purines
138 rdf:type schema:DefinedTerm
139 Nce819a7a369f4040819f1587b5941c24 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
140 schema:name Male
141 rdf:type schema:DefinedTerm
142 Nd4773911f929489589b594fe32b78243 schema:name From the Pulmonology, Heart and Lung Centre, London, England
143 rdf:type schema:Organization
144 Nda5c8149edcf4376be4a4b1907d83a1b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
145 schema:name Coronary Artery Disease
146 rdf:type schema:DefinedTerm
147 Nde34a502890b44e6b0efc35c7c341d4d schema:name doi
148 schema:value 10.1016/j.nuclcard.2008.02.009
149 rdf:type schema:PropertyValue
150 Ne0815b6fbe624913abc2194a42f279c9 schema:name From the Pulmonology, Heart and Lung Centre, London, England
151 rdf:type schema:Organization
152 Ne37a865f5247490a9d244152c074c3ed rdf:first sg:person.01327066420.63
153 rdf:rest Nb573293c1fb94d84903c3d48943a44e4
154 Nf071ad1235054a0ba0dca6a88bea24bf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
155 schema:name Respiration Disorders
156 rdf:type schema:DefinedTerm
157 Nf8495db2ce9240eb943ceebc272e1956 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
158 schema:name Female
159 rdf:type schema:DefinedTerm
160 Nf8834bd8893d4a81a81ca8c581183480 schema:issueNumber 3
161 rdf:type schema:PublicationIssue
162 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
163 schema:name Medical and Health Sciences
164 rdf:type schema:DefinedTerm
165 anzsrc-for:1102 schema:inDefinedTermSet anzsrc-for:
166 schema:name Cardiorespiratory Medicine and Haematology
167 rdf:type schema:DefinedTerm
168 sg:journal.1106202 schema:issn 1071-3581
169 1532-6551
170 schema:name Journal of Nuclear Cardiology
171 rdf:type schema:Periodical
172 sg:person.01012400567.25 schema:affiliation Nd4773911f929489589b594fe32b78243
173 schema:familyName O’Connor
174 schema:givenName B.
175 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01012400567.25
176 rdf:type schema:Person
177 sg:person.01045564377.55 schema:affiliation N82566c25ea484e2a9fe3d4c0a380cc78
178 schema:familyName Barnes
179 schema:givenName Peter J.
180 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01045564377.55
181 rdf:type schema:Person
182 sg:person.01077014765.45 schema:affiliation https://www.grid.ac/institutes/grid.418227.a
183 schema:familyName Mathur
184 schema:givenName Vandana S.
185 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01077014765.45
186 rdf:type schema:Person
187 sg:person.01311065707.38 schema:affiliation Nba6d931d3bd9491389cff46c4c4989f4
188 schema:familyName Hansel
189 schema:givenName Trevor T.
190 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01311065707.38
191 rdf:type schema:Person
192 sg:person.01327066420.63 schema:affiliation Ne0815b6fbe624913abc2194a42f279c9
193 schema:familyName Leaker
194 schema:givenName Brian R.
195 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01327066420.63
196 rdf:type schema:Person
197 sg:person.0654506263.79 schema:affiliation https://www.grid.ac/institutes/grid.418227.a
198 schema:familyName Lieu
199 schema:givenName Hsiao D.
200 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0654506263.79
201 rdf:type schema:Person
202 sg:pub.10.2165/00003088-200645120-00005 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027091187
203 https://doi.org/10.2165/00003088-200645120-00005
204 rdf:type schema:CreativeWork
205 https://doi.org/10.1002/(sici)1098-2299(199611/12)39:3/4<333::aid-ddr14>3.0.co;2-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042024088
206 rdf:type schema:CreativeWork
207 https://doi.org/10.1016/0735-1097(94)90424-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025970600
208 rdf:type schema:CreativeWork
209 https://doi.org/10.1016/0735-6757(93)90138-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016818117
210 rdf:type schema:CreativeWork
211 https://doi.org/10.1016/j.jcmg.2008.02.003 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021315962
212 rdf:type schema:CreativeWork
213 https://doi.org/10.1016/s0140-6736(98)10019-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009352689
214 rdf:type schema:CreativeWork
215 https://doi.org/10.1016/s0165-6147(98)01179-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017804473
216 rdf:type schema:CreativeWork
217 https://doi.org/10.1067/mhj.2001.116070 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012604102
218 rdf:type schema:CreativeWork
219 https://doi.org/10.1152/ajplung.00353.2002 schema:sameAs https://app.dimensions.ai/details/publication/pub.1063195609
220 rdf:type schema:CreativeWork
221 https://doi.org/10.1177/096032719401300407 schema:sameAs https://app.dimensions.ai/details/publication/pub.1063901801
222 rdf:type schema:CreativeWork
223 https://doi.org/10.1378/chest.106.4.1083 schema:sameAs https://app.dimensions.ai/details/publication/pub.1067171984
224 rdf:type schema:CreativeWork
225 https://doi.org/10.1378/chest.127.6.2222 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024504709
226 rdf:type schema:CreativeWork
227 https://doi.org/10.1378/chest.89.3.335 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040848762
228 rdf:type schema:CreativeWork
229 https://doi.org/10.4049/jimmunol.172.12.7726 schema:sameAs https://app.dimensions.ai/details/publication/pub.1076850170
230 rdf:type schema:CreativeWork
231 https://www.grid.ac/institutes/grid.418227.a schema:alternateName Gilead Sciences (United States)
232 schema:name Biostatistics, CV Therapeutics, Palo Alto, Calif.
233 Clinical Research, CV Therapeutics, Palo Alto, Calif.
234 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...